LIC Mutual Fund
When comparing, both lines start at 100. Tradinity's reference for the category: a total-return index (dividends reinvested). The fund's declared benchmark (BSE Healthcare - TRI) is not available to us as a series.
Up to one year: absolute. Longer: annualised. Category = median of Sectoral/Thematic direct-plan Growth funds; index = NIFTY 500 TRI.
| Period | This fund | Category median | NIFTY 500 TRI | Rank in category |
|---|---|---|---|---|
| 1 month | -4.36% | -5.43% | -6.32% | — |
| 3 months | +3.85% | -2.83% | -5.14% | — |
| 6 months | +21.29% | +8.81% | +5.07% | — |
| 1 year | +13.76% | +1.34% | -3.80% | #35 of 224 Top 16% |
| 3 years | +20.83% | +12.83% | +9.14% | #13 of 137 Top 10% |
| 5 years | — | +11.70% | +8.89% | — |
| 10 years | — | +14.63% | +12.66% | — |
| Since launch of NAV data | +20.31% | — | — | — |
| Window | High | Low |
|---|---|---|
| 1 month | 38.3333 | 36.4119 |
| 3 months | 38.4712 | 35.0615 |
| 6 months | 38.4712 | 29.6812 |
| 1 year | 38.4712 | 29.6241 |
A period is a dash when the fund has not existed that long or its NAV history has a hole at the start date — never a partial figure.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | YTD | |
|---|---|---|---|---|---|---|---|
| This fund | — | — | — | — | +43.90% | -3.21% | +13.94% |
| Category median | +14.76% | +32.13% | +5.11% | +32.77% | +22.00% | +4.37% | -2.14% |
| NIFTY 500 TRI | +17.89% | +31.60% | +4.25% | +26.91% | +16.24% | +7.76% | -7.72% |
Tradinity's reference for the category: a total-return index (dividends reinvested). The fund's declared benchmark (BSE Healthcare - TRI) is not available to us as a series.
Twenty checks of five points each: performance, portfolio, operations, and risk against reward. Only checks we have data for are counted.
Risk-free rate 6.06% (3-year annualised return of the NSE 1-day (overnight) rate index). Benchmark-relative ratios use NIFTY 500 TRI. Tradinity's reference for the category: a total-return index (dividends reinvested). The fund's declared benchmark (BSE Healthcare - TRI) is not available to us as a series.
| Ratio | This fund | Category median | Against category |
|---|---|---|---|
| Sharpe ratio | 1.05 | 0.42 | Better |
| Sortino ratio | 1.48 | 0.57 | Better |
| Standard deviation | 14.09% | 15.72% | Better |
| Maximum drawdown | -15.10% | -21.28% | Better |
| Beta | 0.65 | 0.93 | — |
| R-squared | 44.7% | 82.5% | — |
| Jensen's alpha | 12.76% | 3.49% | Better |
| Treynor ratio | 22.58 | 6.74 | Better |
| Information ratio | 1.01 | 0.55 | Better |
| Upside capture | 77.4% | 93.7% | Worse |
| Downside capture | 60.7% | 91.0% | Better |
Computed from this fund's actual NAVs. A SIP buys at the first NAV of each month and is valued at the latest NAV. Past returns do not guarantee future ones.
Weights are % of the scheme's assets from the latest month-end disclosure available to Tradinity. The feed carries weights only: no quantities or rupee values.
Valuation ratios are weighted over the holdings we can match to a company (harmonic mean for P/E) and are withheld when they cover under half the portfolio.
| Equity | 96.93% |
| Cash & Equivalents | 3.07% |
Click a sector to filter the holdings below (holdings map to our sector list where the company is known).
| Holding | Sector | Weight | 3M change | P/E |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | 10.69% | -0.53 pp | 146.5 |
| Divi's Laboratories Ltd | Healthcare | 9.47% | 4.74 pp | 83.9 |
| Torrent Pharmaceuticals Ltd | Healthcare | 6.89% | 0.39 pp | 78.2 |
| Apollo Hospitals Enterprise Limited | Healthcare | 6.62% | 0.10 pp | 74.7 |
| Neuland Laboratories Limited | Healthcare | 5.57% | 0.99 pp | 55.1 |
| Navin Fluorine International Ltd | Chemicals | 5.20% | 1.88 pp | 74.7 |
| Aurobindo Pharma Ltd | Healthcare | 5.02% | -0.12 pp | 37.4 |
| Zydus Lifesciences Ltd | Healthcare | 4.90% | 4.90 pp | 33.3 |
| Aster Dm Quality Care Ltd | Healthcare | 4.67% | 4.67 pp | 207.5 |
| Fortis Healthcare Ltd | Healthcare | 4.16% | -0.53 pp | 257.5 |
| Gland Pharma Ltd | Healthcare | 3.60% | 0.69 pp | 34.3 |
| Global Health Ltd | Healthcare | 3.20% | 1.23 pp | 76.2 |
| Treps | — | 3.17% | -1.00 pp | — |
| Mankind Pharma Ltd | Healthcare | 3.12% | 0.84 pp | 47.4 |
| IPCA Laboratories Ltd | Healthcare | 2.97% | -0.04 pp | 39.3 |
| Artemis Medicare Services Ltd | Healthcare | 2.86% | 0.16 pp | 48.3 |
| Max Healthcare Institute Limited | Healthcare | 2.84% | 0.87 pp | 126.0 |
| Metropolis Healthcare Ltd | Healthcare | 2.82% | 0.15 pp | 27.5 |
| Biocon Limited | Healthcare | 2.77% | 2.77 pp | 597.3 |
| Glenmark Pharmaceuticals Limited | Healthcare | 2.74% | -0.67 pp | 321.6 |
| Onesource Specialty Pharma Ltd | Healthcare | 2.49% | -2.07 pp | 366.7 |
| Cohance Lifesciences Ltd | Healthcare | 2.37% | 2.37 pp | 95.7 |
| Dr. Agarwal's Health Care Limited | Healthcare | 1.94% | -0.15 pp | 330.6 |
Expense ratio by month: Oct 25 1.22% · Nov 25 1.22% · Dec 25 1.22% · Jan 26 1.13% · Feb 26 0.64% · Mar 26 0.64% · Apr 26 1.13% · May 26 1.13% · Jun 26 1.53% · Jul 26 1.42% · Aug 26 1.42% · Sep 26 1.37%
Nil, If units of the Scheme are redeemed or switched out up to 12% of the units (the limit) within 90 days from the date of allotment. 1% of the applicable NAV, If units of the scheme are redeemed or switched out in excess of the limit within 90 days from the date of allotment. Nil, If units of scheme are redeemed or switched out after 90 days from the date of allotment.
The objective of the Scheme is to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors. There is no assurance that the investment objective of the Scheme will be achieved.
Fund house: website · factsheets · monthly portfolio · annual report
Not available: Morningstar rating (proprietary). "NAV history from" is the first NAV we hold.
Returns are computed by Tradinity from each scheme's own published NAV, so they are net of the fund's expenses. Periods over one year are annualised (CAGR). Past performance does not indicate future returns. Only Growth-option schemes are ranked: an IDCW scheme pays cash out of its NAV, so its NAV understates what an investor earned.
